Canagliflozin‐induced renal glutathione distribution mapping in non‐diabetic male rat kidneys
Abstract Canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has direct renoprotective effects beyond lowering blood glucose levels. The inhibition of sodium reabsorption via SGLT2 reduces the overload on proximal tubules, thereby suppressing the generation of reactive oxygen species...
Saved in:
| Main Authors: | Guy Watanabe, Shoichiro Horita, Reika Flora Moriya, Yusuke Masuishi, Shingen Misaka, Shu Taira, Kenju Shimomura, Michio Shimabukuro, Junichiro James Kazama |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Physiological Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.14814/phy2.70320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis
by: Thomas A. Mavrakanas, et al.
Published: (2024-10-01) -
Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01) -
The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01) -
Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
by: Nina A. Petunina, et al.
Published: (2016-12-01) -
Canagliflozin protects cardiovascular function in type 2 diabetic coronary artery disease by regulating natriuretic peptide B
by: Jiarui Zhang, et al.
Published: (2025-08-01)